Hydroxylated cyclopenta[d]pyrimidines as AKT protein kinase inhibitors

The present invention provides compounds, including resolved enantiomers, resolved diastereomers, solvates and pharmaceutically acceptable salts thereof, comprising the Formula I for use in oral dosage forms: Also provided are oral dosage forms comprising these compounds, methods of using the compounds and oral dosage forms of this invention as AKT protein kinase inhibitors and for the treatment of hyperproliferative diseases such as cancer. Further provided are intermediate compounds from the synthesis of these compounds.